Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2445772 | 0.72 | COMT (0.42) | MAPTRIPK1POLB | |
| SCHEMBL10242311 | 0.70 | COMT (0.43) | MAPTRIPK1KDM4EPOLB | |
| SCHEMBL30858971 | 0.66 | MAPT (0.43) | MAPTTSHRKDM4E | |
| SCHEMBL29261677 | 0.66 | MAPT (0.43) | MAPTTSHRKDM4E | |
| Bromide SCHEMBL2497703 | 0.65 | HSD17B10 (0.36) | MAPT | |
| SCHEMBL17845448 | 0.65 | KDM4E (0.41) | MAPTTSHRKDM4EPOLB | |
| SCHEMBL1871602 | 0.63 | KDM4E (0.48) | MAPTTSHRKDM4EPOLB | |
| SCHEMBL31229226 | 0.63 | MAPT (0.47) | MAPTTSHRKDM4E | |
| SCHEMBL1530370 | 0.62 | MAPT (0.64) | MAPTTSHR | |
| SCHEMBL330115 | 0.62 | HSD17B10 (0.37) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516887-B | Thiazole pyrazolopyrimidines as crf1 receptor antagonists | LILLY CO ELI | 2011-11-02 | — | — | CN | disclosed |
| US-8030304-B2 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2094709-B1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | ELI LILLY AND COMPANY | 2010-09-02 | — | — | US | disclosed |
| EP-2094709-A1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101516887-A | Thiazole pyrazolopyrimidines as CRF1 receptor antagonists | LILLY CO ELI (US) | 2009-08-26 | — | — | CN | disclosed |
| WO-2008036579-A1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222339-A1 | Thiazole pyrazolopyrimidines CRF1 receptor antagonists | CRHR1, CRH, CRHR2 | MAPT 1253/4885TSHR 62/4885RIPK1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.